07:53 AM EDT, 09/03/2025 (MT Newswires) -- Novartis ( NVS ) has entered into an additional collaboration with Argo Biopharmaceutical for multiple cardiovascular assets in Argo's pipeline, Argo said Wednesday.

Argo said the new collaboration will allow it to receive a $160 million upfront payment while also becoming eligible for potential milestone and option payments of up to $5.2 billion, as well as tiered royalties from commercial sales.

The new collaboration includes an agreement to investigate Argo's mid-stage ANGPTL3 in a combination trial in dyslipidemia, with an option to license second-generation molecules in the pipeline, Argo said.

The new partnership also includes license to an additional Argo siRNA candidate that is currently in IND-enabling studies, Argo said.

Argo also said Novartis ( NVS ) has expressed its non-binding intention to participate in Argo's next round of equity financing.

This latest collaboration builds on both companies' prior partnership, which was reported in January of last year, for $185 million upfront, over $4 billion in milestones, and a blended royalty and commercial structure in select territories, Argo said.